Neuroimaging in attention-deficit hyperactivity disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) affects an estimated 5 to 7% of children and 2.5% of adults. From the first contemporary description of ADHD in the Diagnostic and Statistical Manual of Mental Disorders (DSM-II) fifty years ago as a hyperkinetic reaction of childhood, the definition has been refined and extended to its current form in DSM-5 as a lifespan neurodevelopmental condition, with specific criteria emphasising the differences between children and adults
Update on the medical management of attention deficit hyperactivity disorder
ADHD is a very costly, chronic condition worldwide, affecting 7-8% of children and 4-5% of adults. It is highly comorbid in patients with other psychiatric disorders. The functioning of patients with ADHD is affected in every aspect of daily living, thus causing lower educational status, often lower socio-economic status, a higher rate of divorce and unemployment, more medical comorbidity and higher medical costs
ADHD and comorbidities
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition affecting all age groups across the world. It is characterised by a persistent pattern of inattention and/ or increased impulsivity and hyperactivity, which is developmentally inappropriate and negatively impacts on the individual’s educational, professional, and personal life
Attempts allowed: 2
70% pass rate